At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
SLXN Silexion Therapeutics Corp
Pre-Mkt 10-13 08:34:34 EDT
0.1782
-0.0364
-16.96%
盘前0.1903
+0.0121+6.79%
08:34 EDT
High0.2082Low0.1766Vol1.27M
Open0.2082D1 Closing0.2146Amplitude14.73%
Mkt Cap2.58MTradable Cap2.58MTotal Shares14.47M
T/O240.60KT/O Rate8.77%Tradable Shares14.47M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Silexion Therapeutics Announces First Patient Successfully Dosed in Phase 2/3 Clinical Trial of Sil204 in Locally Advanced Pancreatic Cancer
THOMSON REUTERS  ·  09-30
Silexion Therapeutics Announces First Patient Successfully Dosed in Phase 2/3 Clinical Trial of Sil204 in Locally Advanced Pancreatic Cancer
Silexion Therapeutics Says Holders Exercise Warrants for 3,216,928 Shares at $0.2603 Each
Reuters  ·  09-29
Silexion Therapeutics Says Holders Exercise Warrants for 3,216,928 Shares at $0.2603 Each
Silexion Therapeutics Announces Exercise of Warrants
GlobeNewswire  ·  09-29
Silexion Therapeutics Announces Exercise of Warrants
Silexion Says Sil204 Uses Native Serum Lipids for Cellular Uptake, Boosts KRAS Knockdown in Preclinical Study
Reuters  ·  09-28
Silexion Says Sil204 Uses Native Serum Lipids for Cellular Uptake, Boosts KRAS Knockdown in Preclinical Study
Silexion Therapeutics Corp - Serum Lipid Depletion Significantly Reduces Sil204 Gene-Knockdown Efficiency
THOMSON REUTERS  ·  09-28
Silexion Therapeutics Corp - Serum Lipid Depletion Significantly Reduces Sil204 Gene-Knockdown Efficiency
Silexion Therapeutics Corp - Sil204 Achieves Robust Gene Silencing in Kras Cancer Cells with Physiological Serum Lipids
THOMSON REUTERS  ·  09-28
Silexion Therapeutics Corp - Sil204 Achieves Robust Gene Silencing in Kras Cancer Cells with Physiological Serum Lipids
Silexion Therapeutics Reports Positive Preclinical Findings for Sil204, Demonstrating Key Mechanism for Endogenous Systemic Uptake in Kras-Driven Cancers
THOMSON REUTERS  ·  09-28
Silexion Therapeutics Reports Positive Preclinical Findings for Sil204, Demonstrating Key Mechanism for Endogenous Systemic Uptake in Kras-Driven Cancers
Silexion Therapeutics Extraordinary Meeting Again Lacks Quorum, Proceeds Under Articles of Association
Reuters  ·  09-26
Silexion Therapeutics Extraordinary Meeting Again Lacks Quorum, Proceeds Under Articles of Association
U.S. Stocks on the MOVE-Greenland Mines, GameStop, Shopify
Reuters  ·  09-22
U.S. Stocks on the MOVE-Greenland Mines, GameStop, Shopify
Silexion Therapeutics to Participate in September 2026 Industry and Investor Conferences
GlobeNewswire  ·  09-09
Silexion Therapeutics to Participate in September 2026 Industry and Investor Conferences
After Moderna’s $44B Oncology Win, Silexion’s Pancreatic Cancer Treatment is Worth Exploring (NASDAQ: SLXN)
TIPRANKS  ·  08-25
After Moderna’s $44B Oncology Win, Silexion’s Pancreatic Cancer Treatment is Worth Exploring (NASDAQ: SLXN)
Silexion Therapeutics Announces Extraordinary Shareholder Meeting
Reuters  ·  08-25
Silexion Therapeutics Announces Extraordinary Shareholder Meeting
Silexion Therapeutics Faces NASDAQ Delisting Notice over Minimum Shareholders’ Equity Shortfall
Reuters  ·  08-22
Silexion Therapeutics Faces NASDAQ Delisting Notice over Minimum Shareholders’ Equity Shortfall
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Atai Beckley N.V. (ATAI), InspireMD (NSPR) and Silexion Therapeutics (SLXN)
TIPRANKS  ·  08-20
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Atai Beckley N.V. (ATAI), InspireMD (NSPR) and Silexion Therapeutics (SLXN)
Silexion Therapeutics Announces Extraordinary General Meeting
Reuters  ·  08-15
Silexion Therapeutics Announces Extraordinary General Meeting
Silexion Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
THOMSON REUTERS  ·  08-14
Silexion Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
U.S. Stocks on the MOVE-Sutro Biopharma, Humacyte
Reuters  ·  08-13
U.S. Stocks on the MOVE-Sutro Biopharma, Humacyte
Top Premarket Decliners
MT Newswires Live  ·  08-12
Top Premarket Decliners
Silexion Therapeutics Prices USD 2.5 Million Public Offering at USD 0.65 Per Share with Warrants
Reuters  ·  08-12
Silexion Therapeutics Prices USD 2.5 Million Public Offering at USD 0.65 Per Share with Warrants
Silexion Therapeutics Announces Pricing of $2.5 Million Public Offering
THOMSON REUTERS  ·  08-12
Silexion Therapeutics Announces Pricing of $2.5 Million Public Offering

Introduction

Company Name.
Silexion Therapeutics Corp
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Moringa Acquisition Corp does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or other similar business combination with one or more businesses. The company focuses on pursuing opportunities in technology-based businesses or industries in Israel. Moringa Acquisition Corp was incorporated in 2020 and is based in New York, New York.
Issue price:
--